LaShell Robinson

home / authors / lashell-robinson

LaShell Robinson is the executive director and global head for global feasibility and trial equity at Takeda Pharmaceuticals.

Articles

LaShell Robinson on Takeda’s Initiative to Improve Research Diversity

LaShell Robinson on Takeda’s Initiative to Improve Research Diversity

Maddi Hebebrand, MC, Associate Editor;LaShell Robinson
March 5th 2025

Robinson shared insights into how the company is working to fight clinical research disparities.

Latest Updated Articles

2 KOLs are featured in this series.
Published: September 19th 2024 | Updated: September 26th 2024
Final Thoughts: The Importance of Comparative Studies in AD
POLL: “Lip Flips” or Lip Filler? Analyzing the Latest Trends in Lip Augmentation
Published: February 28th 2025 | Updated: May 11th 2025
POLL: “Lip Flips” or Lip Filler? Analyzing the Latest Trends in Lip Augmentation
CT-P39 is Just as Effective as Omalizumab for Chronic Spontaneous Urticaria Treatment
Published: January 23rd 2025 | Updated: May 11th 2025
CT-P39 is Just as Effective as Omalizumab for Chronic Spontaneous Urticaria Treatment
The Complex World of Urticaria: Insights from Jason Hawkes, MD, MS
Published: February 13th 2025 | Updated: May 11th 2025
The Complex World of Urticaria: Insights from Jason Hawkes, MD, MS
Q&A: Thomas Casale, MD, Discusses Abstract on Dupilumab and Significant Itch, Hive Reduction in Chronic Spontaneous Urticaria
Published: March 3rd 2025 | Updated: May 11th 2025
Q&A: Thomas Casale, MD, Discusses Abstract on Dupilumab and Significant Itch, Hive Reduction in Chronic Spontaneous Urticaria
Q&A: Jonathan Bernstein, MD, FAAAAI, Discusses Advances in Chronic Spontaneous Urticaria Treatments and AAAAI Data
Published: March 5th 2025 | Updated: May 11th 2025
Q&A: Jonathan Bernstein, MD, FAAAAI, Discusses Advances in Chronic Spontaneous Urticaria Treatments and AAAAI Data
© 2025 MJH Life Sciences

All rights reserved.